Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1692592

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1692592

Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025

PUBLISHED:
PAGES: 75 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2400
PDF (Multi-User License)
USD 4300

Add to Cart

Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025 Report Highlights & Findings:

  • First VISTA Inhibitor Drug Approval By 2028
  • US Dominating Global VISTA Inhibitor Clinical Trials Landscape
  • Insight On Ongoing Clinical Trials By Company, Country, Indication & Phase
  • Key Drugs Clinical Study Initiation & Completion Year Overview
  • Global & Regional Market Development Insight By Indication
  • Global VISTA Inhibitors Market Dynamics & Competitive Landscape

The landscape of cancer immunotherapy has witnessed remarkable transformations in recent years, with immune checkpoint inhibitors revolutionizing treatment approaches for various malignancies. With the massive success of first generation immune checkpoint inhibitors, such as pembrolizumab and Nivolumab, researchers have now focused their efforts in identifying newer immune checkpoint proteins. Among the emerging next-generation targets in this innovative field is the V-domain immunoglobulin suppressor of T cell activation (VISTA), which represents a promising yet under-explored avenue for potential therapeutic interventions across a range of indications.

VISTA, a critical immune checkpoint protein, plays a nuanced role in regulating immune responses, particularly within the tumor microenvironment. Unlike more extensively studied checkpoint molecules like PD-1 and CTLA-4, VISTA remains a relatively nascent target with significant untapped potential. Researchers have increasingly recognized its importance in modulating T cell activation and suppressing anti-tumor immune responses, making it an intriguing candidate for targeted immunotherapeutic strategies.

The current immunotherapy landscape demonstrates considerable promise for VISTA targeted approaches, drawing parallels with the remarkable success of existing immune checkpoint inhibitors. The groundbreaking achievements of PD-1 and CTLA-4 inhibitors have paved the way for more sophisticated and precise immunomodulatory interventions. These precedents provide robust scientific validation and investor confidence in exploring novel checkpoint targets like VISTA, suggesting a potentially transformative therapeutic approach.

Among the most promising developments in VISTA targeted therapy is CA-170, an innovative oral small molecule developed by Aurigene Oncology and Curis. This compound represents a sophisticated dual inhibitor targeting both VISTA and PD-L1, offering several compelling advantages over traditional antibody-based approaches. The molecule's oral administration format, reduced complexity, and potential for more manageable immune-related adverse events distinguish it from conventional immunotherapeutic strategies.

The strategic collaboration between Aurigene and Curis highlights the significant interest and potential commercial viability of VISTA targeted therapies. By dividing development rights across different geographical regions, the partnership underscores the global scientific community's recognition of VISTA's therapeutic potential. The ongoing late-phase clinical trials, particularly the phase 2b/3 studies investigating CA-170's efficacy in non-small cell lung cancer, represent a critical milestone in understanding the molecule's clinical utility.

Preclinical and early stage research has unveiled VISTA's complex immunomodulatory mechanisms. Unlike some checkpoint proteins, VISTA exhibits unique characteristics in suppressing T cell responses, suggesting nuanced implications for cancer immunotherapy. Preliminary studies indicate that VISTA's inhibition could potentially reinvigorate anti-tumor immune responses, offering a complementary or alternative approach to existing checkpoint blockade strategies.

The lack of approved VISTA-targeted therapies presents both a challenge and an opportunity for researchers and pharmaceutical developers. The uncharted nature of this therapeutic domain invites innovative approaches and allows for creative exploration of VISTA's potential mechanisms. Researchers are particularly intrigued by VISTA's potential in overcoming resistance mechanisms observed with other checkpoint inhibitors, potentially offering new hope for patients with treatment-resistant malignancies.

Scientific interest in VISTA extends beyond oncology, with emerging research suggesting potential applications in autoimmune disorders and inflammatory conditions. This broader therapeutic landscape further amplifies the molecule's significance and underscores the importance of continued investigative efforts. The multifaceted nature of VISTA's immunomodulatory functions presents a complex yet exciting frontier for translational research.

As the scientific community continues to unravel VISTA's intricate roles in immune regulation, the coming years are likely to witness accelerated research and clinical development. The potential for developing targeted therapies that can modulate immune responses with greater precision represents a significant advancement in personalized medicine. While challenges remain, the foundational research and ongoing clinical investigations paint an optimistic picture for VISTA-targeted therapeutic strategies.

Table of Contents

1. VISTA As Emerging Immune Checkpoint

  • 1.1 What Is VISTA Inhibition?
  • 1.2 Structure & Biology Of VISTA Protein
  • 1.3 Mechanism Of Action Of VISTA Inhibitors

2. VISTA As Inhibitory & Costimulatory Checkpoint

  • 2.1 VISTA As Inhibitory Immune Checkpoint
  • 2.2 VISTA As Costimulatory Checkpoint
  • 2.3 VISTA Inhibition v/s Conventional Immune Checkpoint Inhibitors

3. Significance Of VISTA In Disease Progressiopn & Cure

  • 3.1 Role Of VlSTA In Facilitating Cancer Progression
  • 3.2 VISTA As Potential Cancer Biomarker
  • 3.3 VISTA As Therapeutic Target In Autoimmune Diseases

4. Global VISTA Inhibitors Market & Clinical Development Outlook

  • 4.1 Current Scenario
  • 4.2 Future Opportunities

5. VISTA Targeted Therapies Trends & Clinical Innovation By Indication

  • 5.1 Solid Cancers
  • 5.2 Hematological Cancers
  • 5.3 Autoimmune & Inflammatory Disorders

6. VISTA Targeted Therapies Trends & Clinical Innovation By Region

  • 6.1 US
  • 6.2 Europe
  • 6.3 India
  • 6.4 Australia

7. Global VISTA Inhibitors Clinical Trials Overview

  • 7.1 By Country
  • 7.2 By Indication
  • 7.3 By Organization
  • 7.4 By Phase

8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

  • 8.1 Preclinical
  • 8.2 Phase I
  • 8.3 Phase I/II
  • 8.4 Phase III

9. Global VISTA Inhibitors Market Dynamics

  • 9.1 Market Drivers
  • 9.2 Market Challenges

10. Competitive Landscape

  • 10.1 Aurigene Discovery Technologies
  • 10.2 Curis
  • 10.3 Hummingbird Bioscience
  • 10.4 Kineta
  • 10.5 PharmAbcine
  • 10.6 Sensei Biotherapeutics

List of Figures

  • Figure 1-1: VISTA Protein - Structure
  • Figure 1-2: VISTA - Binding Partners
  • Figure 1-3: VISTA Inhibition - Basic Mechanism
  • Figure 2-1: VISTA - Role In Cancer Immunotherapy
  • Figure 2-2: VISTA - Role In Autoimmune Diseases
  • Figure 2-3: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
  • Figure 3-1: VISTA Interaction With Immune Cells
  • Figure 3-2: VISTA - Mechanisms Of Immune Suppression
  • Figure 3-3: Dual Role Of VISTA In Cancer
  • Figure 3-4: VISTA As Predictive Biomarker
  • Figure 3-5: Autoimmune Diseases - VISTA Agonism
  • Figure 4-1: Future Market Opportunities
  • Figure 5-1: Solid Tumors - VISTA Role In Tumor Immune Evasion
  • Figure 5-2: SNS-101-2-1 Phase 1/2 (NCT05864144) Study - Initiation & Completion Year
  • Figure 5-3: HMBD-002-V4C26-01 Phase 1/2 (NCT05082610) Study - Initiation & Completion Year
  • Figure 5-4: Hematological Cancers - Mechanisms Of Immune Evasion By VISTA
  • Figure 5-5: Autoimmune & Inflammatory Disorders - VISTA As Ligand On APCs
  • Figure 5-6: Autoimmune & Inflammatory Disorders - VISTA As Receptor On T Cells
  • Figure 5-7: Kings College London & Dartmouth College VISTA Patent - Grant & Expiration Year
  • Figure 6-1: MarkV-01/KEYNOTE-E80 Phase 1 (NCT05957081) Study - Initiation & Completion Year
  • Figure 7-1: Global - Number Of VISTA Inhibitors In Clinical Trials By Country, 2025
  • Figure 7-2: Global - Number Of VISTA Inhibitors In Clinical Trials By Indication, 2025
  • Figure 7-3: Global - Number Of VISTA Inhibitors In Clinical Trials By Organization, 2025
  • Figure 7-4: Global - Number Of VISTA Inhibitors In Clinical Trials By Phase, 2025
  • Figure 9-1: Market Drivers & Opportunities
  • Figure 9-2: Market Challenges & Restraints

List of Tables

  • Table 5-1: VISTA - Role In Autoimmune & Inflammatory Disorders
  • Table 6-1: US - Ongoing Clinical Trials for VISTA Inhibitors
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!